Naturally occurring drug resitance substitutions in the NS5A and NS5B regions in Hepatitis C virus genotype 2 and response to sofosbuvir plus ribavirin therapy

被引：0
|
作者：
Hayashi, K. [1 ]
Ishigami, M. [1 ]
Ishizu, Y. [1 ]
Kazuya, T. [1 ]
Honda, T. [1 ]
Hirooka, Y. [1 ]
Goto, H. [1 ]
机构：
[1] Nagoya Univ, Gastroenterol & Hepatol, Nagoya, Aichi, Japan
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30813-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-373
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [21] Drug Resistance Mutations in the Ns3 and NS5A Regions in Patients With Hepatitis C Virus Genotype 1b and Response to Telaprevir Plus Pegylated-Interferon-Alpha 2B and Ribavirin Combination Therapy
    Hayashi, Kazuhiko
    Ishigami, Masatoshi
    Ishizu, Yoji
    Kuzuya, Teiji
    Honda, Takashi
    Katano, Yoshiaki
    Hirooka, Yoshiki
    Goto, Hidemi
    GASTROENTEROLOGY, 2014, 146 (05) : S979 - S979
  • [22] Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
    Sarrazin, Christoph
    Dvory-Sobol, Hadas
    Svarovskaia, Evguenia S.
    Doehle, Brian P.
    Pang, Phillip S.
    Chuang, Shu-Min
    Ma, Julie
    Ding, Xiao
    Afdhal, Nezam H.
    Kowdley, Kris V.
    Gane, Edward J.
    Lawitz, Eric
    Brainard, Diana M.
    McHutchison, John G.
    Miller, Michael D.
    Mo, Hongmei
    GASTROENTEROLOGY, 2016, 151 (03) : 501 - +
  • [23] The prevalence of naturally occurring resistance mutations against NS3 protease inhibitors, NS5A replication complex inhibitors, and NS5B polymerase inhibitors in patients with hepatitis C virus genotype 1b
    Hayashi, Kazuhiko
    Ishigami, Masatoshi
    Ishizu, Yoji
    Kuzuya, Teiji
    Honda, Takashi
    Katano, Yoshiaki
    Hirooka, Yoshiki
    Goto, Hidemi
    HEPATOLOGY, 2014, 60 : 896A - 897A
  • [24] Naturally occurring drug related mutations to inhibitors targeting the NS3/4A, NS5B and NS5A regions in HCV 1b carriers in Israel: are they affecting therapy?
    Mor, O.
    Gozlan, Y.
    Peleg, O.
    Mendelson, E.
    Sandak, Y.
    Hassid, A.
    Tsaraf, K.
    Weizmann, E.
    Ben Ari, Z.
    ANTIVIRAL THERAPY, 2014, 19 : A106 - A106
  • [25] Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A
    Moriyama, Masaru
    Kato, Naoya
    Otsuka, Motoyuki
    Shao, Run-Xuan
    Taniguchi, Hiroyoshi
    Kawabe, Takao
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2007, 1 (02) : 302 - 310
  • [26] Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A
    Moriyama, Masaru
    Kato, Naoya
    Otsuka, Motoyuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A21 - A21
  • [27] Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A
    Masaru Moriyama
    Naoya Kato
    Motoyuki Otsuka
    Run-Xuan Shao
    Hiroyoshi Taniguchi
    Takao Kawabe
    Masao Omata
    Hepatology International, 2007, 1 : 302 - 310
  • [28] Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B
    Hamamoto, I
    Nishimura, Y
    Okamoto, T
    Aizaki, H
    Liu, MY
    Mori, Y
    Abe, T
    Suzuki, T
    Lai, MMC
    Miyamura, T
    Moriishi, K
    Matsuura, Y
    JOURNAL OF VIROLOGY, 2005, 79 (21) : 13473 - 13482
  • [29] THE ROLE OF SUBSTITUTIONS IN THE CORE AND NS5A REGION OF HEPATITIS C VIRUS GENOTYPE 1B ON RESPONSIVENESS TO PEGYLATED INTERFERON AND RIBAVIRIN COMBINATION THERAPY
    Katano, Y.
    Ishigami, M.
    Nakano, I.
    Hayashi, K.
    Honda, T.
    Goto, H.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S228 - S228
  • [30] Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C
    Ahmed, Hala Rady
    Waly, Nancy G. F. M.
    Abd El-Baky, Rehab Mahmoud
    Yahia, Ramadan
    Hetta, Helal F.
    Elsayed, Amr M.
    Ibrahem, Reham Ali
    PLOS ONE, 2021, 16 (04):
12345